Search
Benzydamine
go.drugbank.com/drugs/DB09084ApprovedInvestigationaldrug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an
Mixtures: TANTUM VERDE DUO 22,5 MG+18 MG/15 ML GARGARA, TANTUM VERDE DUO FORTE 0,30 / %0,12 ORAL SPREY, ÇÖZELTİProducts: TANTUM VERDE P, Nu-benzydamine Oral RinsePanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. … Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesMisoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the
Mixtures: DICLOENAC SODIUM and MISOPROSTOL DR, Diclofenac sodium and Misoprostol DRPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A198984] Deregulated FGFR signalling pathway can lead the development of oncogenes and tumour-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of … unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsChromium
go.drugbank.com/drugs/DB11136ApprovedInvestigationalHumans can be exposed to chromium via ingestion, inhalation, and dermal or ocular exposure [L1983]. … Chromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label].
Mixtures: Dp 2000, Calcium With Mg Zn Mn Cu CR Si and Vit. C & DEliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesDeferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 InhibitorsNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult pati...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsSertraline
go.drugbank.com/drugs/DB01104ApprovedInvestigationalSertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in th...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: Nu-sertraline Capsules, Ran-sertralineCod liver oil
go.drugbank.com/drugs/DB11321ApprovedNutraceuticalVet approvedAlso being a rich source of vitamin A and D, cod liver oil can be taken orally as daily supplements. … It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria.